Ind Swift Laboratories Share Price

Ind-Swift Laboratories Limited is an India-based company, which is engaged in the business of manufacturing active pharmaceutical ingredients (APIs), intermediates and formulations. The Company operates in the Pharmaceutical Business segment. It also focuses on manufacturing formulations. The Company’s products include APIs and Impurities. Its APIs therapeutic category includes Macrolide Antibiotic, Cardiovascular, Antihistaminic, Antidiabetic, Antipsyhotic, Bone Resorption Inhibitor, and Aromatase Inhibitor. Its products include Clarithromycin, Clarithromycin Coated Granules, Clarithromycin Citrate, Atorvastatin Calcium Crystalline, Atorvastatin Calcium Amorphous, Clopidogrel HCl, Ezetimibe, Ivabradine Oxalate, Ranolazine, Aripiprazole, Risedronate Sodium, Ropinirole HCl, Cinacalcet HCl, Letrozole, and Anastrozole. Its products under development include Sitagliptin Phosphate, Mirabegron, Bempedoic Acid, Lasmiditan, and Eltrombopag Olamine.As of 26 May 2026, Ind Swift Laboratories share price is ₹132.18. The stock opened at ₹132.80, compared to its previous close of ₹131.79. During today's trading session, Ind Swift Laboratories share price moved in the range of ₹129.50 to ₹135.90, with an average price of ₹132.70 for the day. Looking at its last 52-week, the stock has touched a low of ₹129.50 and a high of ₹135.90. On the performance front, Ind Swift Laboratories share price has increased by 40.56% over the last six months and is up 83.07% on a year-on-year basis.

The market capitalization of Ind Swift Laboratories is ₹1,146 Crs, with a P/E ratio of 4.6 and a dividend yield of 0.00%.